Compare Stocks: QNRX, UG, CPHI, and MIRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPHI China Pharma	$0.71 -2.5%	$0.84	$0.38 ▼ $19.19	$30.54M	1.04	2.01 million shs	303,101 shs
MIRA MIRA Pharmaceuticals	$0.63 -3.9%	$0.77	$0.60 ▼ $1.83	$26.57M	1.48	165,859 shs	123,158 shs
QNRX Quoin Pharmaceuticals	$3.90 -3.2%	$5.71	$3.25 ▼ $23.50	$18.74M	1.56	50,456 shs	31,730 shs
UG United-Guardian	$6.84 -0.1%	$7.12	$5.58 ▼ $8.45	$31.43M	0.95	11,084 shs	7,864 shs

10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPHI China Pharma	0.00%	-18.45%	-0.15%	-35.46%	-62.44%
MIRA MIRA Pharmaceuticals	0.00%	-15.18%	-16.73%	-34.13%	-52.10%
QNRX Quoin Pharmaceuticals	0.00%	-13.33%	-44.37%	-8.02%	-74.46%
UG United-Guardian	0.00%	-3.53%	-5.39%	-9.40%	-6.94%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPHI China Pharma	$0.71 -2.5%	$0.84	$0.38 ▼ $19.19	$30.54M	1.04	2.01 million shs	303,101 shs
MIRA MIRA Pharmaceuticals	$0.63 -3.9%	$0.77	$0.60 ▼ $1.83	$26.57M	1.48	165,859 shs	123,158 shs
QNRX Quoin Pharmaceuticals	$3.90 -3.2%	$5.71	$3.25 ▼ $23.50	$18.74M	1.56	50,456 shs	31,730 shs
UG United-Guardian	$6.84 -0.1%	$7.12	$5.58 ▼ $8.45	$31.43M	0.95	11,084 shs	7,864 shs

10 Best Stocks to Own in Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPHI China Pharma	0.00%	-18.45%	-0.15%	-35.46%	-62.44%
MIRA MIRA Pharmaceuticals	0.00%	-15.18%	-16.73%	-34.13%	-52.10%
QNRX Quoin Pharmaceuticals	0.00%	-13.33%	-44.37%	-8.02%	-74.46%
UG United-Guardian	0.00%	-3.53%	-5.39%	-9.40%	-6.94%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPHI China Pharma	0.00	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	2.33	Hold	$3.50	453.53% Upside
QNRX Quoin Pharmaceuticals	2.50	Moderate Buy	$17.00	335.90% Upside
UG United-Guardian	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest QNRX, UG, CPHI, and MIRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/12/2026	QNRX Quoin Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$14.00
10/12/2026	QNRX Quoin Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$14.00
9/23/2026	QNRX Quoin Pharmaceuticals	Lake Street Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$20.00
9/17/2026	MIRA MIRA Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$3.50
8/20/2026	MIRA MIRA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/6/2026	MIRA MIRA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
7/21/2026	UG United-Guardian	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C-) ➝ Hold (C)
7/20/2026	QNRX Quoin Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)

(Data available from 10/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPHI China Pharma	$3.91M	7.80	N/A	N/A	$0.70 per share	1.01
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.25 per share	N/A
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	$15.64 per share	N/A
UG United-Guardian	$11.21M	2.80	$0.48 per share	14.19	$2.44 per share	2.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPHI China Pharma	-$3.08M	-$0.43	N/A	N/A	N/A	-85.56%	-63.93%	-31.42%	N/A
MIRA MIRA Pharmaceuticals	-$10.44M	-$1.24	N/A	N/A	N/A	N/A	-106.95%	-104.18%	12/2/2026 (Estimated)
QNRX Quoin Pharmaceuticals	-$15.81M	-$25.18	N/A	N/A	N/A	N/A	-489.57%	-221.17%	11/5/2026 (Estimated)
UG United-Guardian	$2.11M	$0.54	12.67	N/A	N/A	22.01%	22.24%	19.12%	N/A

Latest QNRX, UG, CPHI, and MIRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	QNRX Quoin Pharmaceuticals	-$1.6083	N/A	N/A	N/A	N/A	N/A
8/14/2026	Q2 2026	QNRX Quoin Pharmaceuticals	-$1.61	-$1.90	-$0.29	-$1.90	N/A	N/A
8/12/2026	Q2 2026	MIRA MIRA Pharmaceuticals	N/A	-$0.03	N/A	-$0.03	N/A	N/A
8/7/2026	Q2 2026	UG United-Guardian	N/A	$0.16	N/A	$0.16	N/A	$3.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPHI China Pharma	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UG United-Guardian	$0.60	8.77%	-5.11%	111.11%	1 Years

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPHI China Pharma	0.22	0.79	0.26
MIRA MIRA Pharmaceuticals	N/A	200.08	200.08
QNRX Quoin Pharmaceuticals	N/A	1.76	1.76
UG United-Guardian	N/A	7.32	6.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPHI China Pharma	N/A
MIRA MIRA Pharmaceuticals	35.16%
QNRX Quoin Pharmaceuticals	8.63%
UG United-Guardian	23.16%

Insider Ownership

Company	Insider Ownership
CPHI China Pharma	6.40%
MIRA MIRA Pharmaceuticals	19.89%
QNRX Quoin Pharmaceuticals	7.54%
UG United-Guardian	29.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPHI China Pharma	221	43.02 million	15.92 million	Not Optionable
MIRA MIRA Pharmaceuticals	2	42.02 million	33.66 million	Not Optionable
QNRX Quoin Pharmaceuticals	6	4.80 million	4.44 million	Not Optionable
UG United-Guardian	25	4.59 million	3.26 million	Not Optionable

QNRX, UG, CPHI, and MIRA Headlines

Recent News About These Companies

United-Guardian (NASDAQ:UG) versus Royalty Pharma (NASDAQ:RPRX) Head-To-Head Comparison

October 11, 2026 | americanbankingnews.com

How United-guardian Inc. (UG) Affects Rotational Strategy Timing

September 24, 2026 | news.stocktradersdaily.comN

Upside Gold Announces September Investor Outreach Schedule

September 16, 2026 | thenewswire.comT

UG Q2 Earnings Rise Y/Y on Strong Cosmetic Ingredient Sales

August 14, 2026 | zacks.com

United-Guardian: Q2 Earnings Snapshot

August 7, 2026 | wtop.comW

United-Guardian Reports Second Quarter Results

August 7, 2026 | globenewswire.com

United-Guardian Insider Trading Activity | NASDAQ:UG | Benzinga

July 16, 2026 | benzinga.com

United-Guardian Declares Cash Dividend

July 16, 2026 | globenewswire.com

UG Outperforms Industry in 6 Months: Buy, Sell or Hold the Stock?

July 8, 2026 | zacks.com

Engages Danayi Capital Corp. To Provide Digital Marketing Services

June 12, 2026 | thenewswire.comT

Upside Gold Corp. Announces Closing of $5 Million Brokered Private Placement

June 12, 2026 | thenewswire.comT

Upside Gold Corp. Announces Closing of $5 Million Brokered Private Placement

June 12, 2026 | thenewswire.comT

Upside Gold Announces Fully Permitted Drill Program at the Kena Gold-Copper Project

May 27, 2026 | thenewswire.comT

United-Guardian Q1 Earnings Rise Y/Y on Strong Renacidin Demand

May 18, 2026 | zacks.com

United-Guardian, Inc. (UG) Shareholder/Analyst Call Transcript

May 13, 2026 | seekingalpha.com

Upside Gold Corp. Finalizes Acquisition of Strategic High-Grade Gold Claims Adjacent to the Kena Project

May 13, 2026 | thenewswire.comT

United-Guardian Reports First Quarter Results

May 8, 2026 | globenewswire.com

Upside Gold Corp. Signs LOI For Strategic Claims Adjacent To The Kena Property

April 27, 2026 | thenewswire.comT

Upside Gold Corp. Announces Grant Of Stock Options

April 9, 2026 | thenewswire.comT

United-Guardian 2025 Earnings Fall Y/Y Amid Weak Sales Trends

March 31, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

QNRX, UG, CPHI, and MIRA Company Descriptions

China Pharma NYSE:CPHI

$0.71 -0.02 (-2.47%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$0.70 -0.01 (-1.68%)

As of 10/16/2026 07:59 PM Eastern

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

MIRA Pharmaceuticals NASDAQ:MIRA

$0.63 -0.03 (-3.92%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$0.65 +0.02 (+3.43%)

As of 10/16/2026 05:37 PM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Quoin Pharmaceuticals NASDAQ:QNRX

$3.90 -0.13 (-3.23%)

Closing price 10/16/2026 03:59 PM Eastern

Extended Trading

$4.00 +0.10 (+2.56%)

As of 10/16/2026 06:50 PM Eastern

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

United-Guardian NASDAQ:UG

$6.84 -0.01 (-0.15%)

Closing price 10/16/2026 03:59 PM Eastern

Extended Trading

$6.83 -0.01 (-0.09%)

As of 10/16/2026 04:04 PM Eastern

United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary specialty industrial products in the United States and internationally The company offers cosmetic ingredients, including LUBRAJEL, a line of water-based gel formulation for sensory enhancement, lubrication, and texture to personal care products; LUBRAJEL NATURAL for skin moisturizing; LUBRAJEL MARINE that develops natural products using naturally derived polymers; LUBRAJEL OlL NATURAL, which makes luxuriant textures without adding viscosity; LUBRAJEL TERRA, a multifunctional, moisturizing hydrogel products; LUBRASIL II SB, a formulation of LUBRAJEL; LUBRAJEL II XD; B-122, a powdered lubricant used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; and ORCHID COMPLEX, an oil-soluble base for extract of fresh orchids used in fragrance products, such as perfumes and toiletries. Its medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL MGL, a medical lubricant with a lower viscosity medical lubricant; LUBRAJEL LC, LUBRAJEL BA, and LUBRAJEL FA, which are formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. The company's pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial used in urology. Its industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. The company also conducts research and product development of cosmetic ingredients. The company was founded in 1942 and is based in Hauppauge, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNRX, UG, CPHI, and MIRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNRX, UG, CPHI, and MIRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNRX, UG, CPHI, and MIRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

QNRX, UG, CPHI, and MIRA Company Descriptions

China Pharma NYSE:CPHI

MIRA Pharmaceuticals NASDAQ:MIRA

Quoin Pharmaceuticals NASDAQ:QNRX

United-Guardian NASDAQ:UG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNRX, UG, CPHI, and MIRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNRX, UG, CPHI, and MIRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNRX, UG, CPHI, and MIRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

QNRX, UG, CPHI, and MIRA Company Descriptions

China Pharma NYSE:CPHI

MIRA Pharmaceuticals NASDAQ:MIRA

Quoin Pharmaceuticals NASDAQ:QNRX

United-Guardian NASDAQ:UG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools